News | July 01, 2014

50th Heart Failure Patient Treated With Revivent Myocardial Anchoring System

Adoption of less-invasive procedure spreads across Western Europe

Revivent Myocardial Anchoring System BioVentrix 50th Heart Failure Treatment

July 1, 2014 — BioVentrix announced the successful completion of it 50th clinical case using the Revivent myocardial anchoring system in a 74-year-old male at the OLV Hospital in Aalst, Belgium. The case comes on the heels of other successful cases performed recently in Germany, Italy and the United Kingdom.

Performed by OLV staff surgeons Filip Casselman, M.D., Ph.D., and Bernard Stockman, M.D., the case marks the first time that the Less Invasive Ventricular Enhancement or LIVE procedure has been performed in Belgium. Recognized as a top-tier research facility, OLV is particularly well known for its adoption of groundbreaking technology in the fields of cardiology and cardiovascular surgery.

"OLV remains at the forefront of implementing promising less-invasive surgical technologies to address the overwhelming need for better heart failure treatment options,” said Casselman. “The adoption of the Revivent system allows us to treat the underlying cause of heart failure by reshaping the left ventricle of the heart to operate more efficiently. Immediately after placement of the device, the patient’s ejection fraction, the most revealing measure of heart function, had already improved.”

Prior to the Revivent system, reshaping of the left ventricle used an invasive procedure known as surgical ventricular reconstruction (SVR) to remove the scarred, non-functioning tissue created by a heart attack. The invasive nature of SVR limits its use because it requires stopping the patient’s heart and supporting it with cardiopulmonary (heart-lung) bypass while incisions into the heart muscle are made to remove the tissue. Placement of the Revivent System via the LIVE procedure obviates these requirements. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls. The anchors are then pulled toward one another, effectively excluding the scarred, and non-functioning heart wall. The efficiency of the remaining heart muscle is immediately improved, by as much as 30-40 percent.[i] Presentation of recent scientific data indicates that in 92 percent of patients, the efficacy results were durable beyond one year.[ii]

For more information:


1.Wechsler, A. et al, Clinical benefits twelve months after less invasive ventricular restoration operations without ventriculotomy. Abstract 104 at the 27th annual meeting of the European Society of Cardio-Thoracic Surgery, 07 Oct. 2013, Vienna, Austria.


Related Content

Videos | Structural Heart | September 14, 2018
A discussion with William O’Neill, M.D., director of the Henry Ford...
A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation. Abbott Mitraclip device.

A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation.

News | Structural Heart | May 11, 2018
May 11, 2018 — The post-approval study evaluating the safety and efficacy of MitraClip in a real-world, commercial se
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart | January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Videos | Structural Heart | November 09, 2016
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart | August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation
News | Structural Heart | May 16, 2016
At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a...
CABG, mitral valve repair, ischemic mitral regurgitation, IMR, study, ACC 2016
News | Structural Heart | April 11, 2016
Just-released two-year follow-up data comparing coronary-artery bypass grafting (CABG) with combined CABG and mitral-...
V-Wave Interarterial Shunt, first human results, The Lancet, heart failure, HF
News | Structural Heart | March 28, 2016
V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF),...
News | Structural Heart | March 02, 2016
Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards...
Overlay Init